Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global secondary hyperparathyroidism treatment market size was valued at USD 3.17 billion in 2024. The market is projected to grow from USD 3.34 billion in 2025 to USD 4.58 billion by 2031, exhibiting a CAGR of 5.5% during the forecast period.
Secondary hyperparathyroidism is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) due to chronic kidney disease or vitamin D deficiency. This condition leads to abnormal calcium and phosphorus metabolism, requiring targeted therapeutic interventions. The treatment landscape includes calcimimetics, vitamin D analogs, phosphate binders, and surgical parathyroidectomy in severe cases.
The market growth is driven by increasing prevalence of chronic kidney disease worldwide, rising geriatric population, and improved diagnostic technologies. Furthermore, rising healthcare expenditure in emerging economies and strategic collaborations among pharmaceutical companies are accelerating market expansion. However, high treatment costs and side effects associated with long-term medication use remain key challenges. Market players like Amgen and Sanofi continue to invest in R&D for novel therapies, with recent advances in calcimimetics showing promising clinical outcomes.
Increasing Prevalence of Chronic Kidney Disease
The growing incidence of chronic kidney disease (CKD) is a primary driver for the secondary hyperparathyroidism treatment market. Approximately 15% of adults in the U.S. have CKD, and up to 50% of patients with stage 5 CKD develop secondary hyperparathyroidism. This creates a significant demand for effective treatments to manage mineral and bone disorders associated with renal failure.
Advancements in Calcimimetic Therapies
The development of novel calcimimetic drugs like etelcalcetide and cinacalcet has revolutionized treatment approaches. These therapies reduce parathyroid hormone (PTH) levels more effectively than traditional vitamin D analogs, with studies showing up to 60% reduction in serum PTH levels in dialysis patients.
The global dialysis population is projected to exceed 5 million by 2025, creating sustained demand for secondary hyperparathyroidism treatments.
Rising healthcare expenditure in emerging economies and improved diagnosis rates are further contributing to market growth, with greater awareness about bone-mineral disorders in CKD patients.
MARKET CHALLENGES
High Treatment Costs and Compliance Issues
Calcimimetic drugs remain expensive, with annual treatment costs often exceeding $10,000 per patient. This creates barriers in price-sensitive markets and developing countries where reimbursement policies may not cover these medications adequately.
Other Challenges
Adverse Effects Management
Therapeutic options currently available carry risks of hypocalcemia, gastrointestinal disturbances, and cardiovascular effects, requiring careful monitoring and dose adjustments that complicate treatment regimens.
Stringent Regulatory Requirements
The complex pathophysiology of secondary hyperparathyroidism necessitates rigorous clinical trials for new drug approvals. Regulatory bodies require extensive data on long-term outcomes, delaying market entry for novel therapies. Recent safety concerns about calcimimetics' cardiovascular effects have further increased scrutiny.
Biosimilars and Combination Therapies
The impending patent expirations of key drugs present opportunities for biosimilar development. Research into combination therapies that address multiple aspects of CKD-mineral and bone disorder (CKD-MBD) could open new treatment paradigms expected to gain 30% market share by 2030.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Calcimimetics are emerging as an innovative therapeutic approach due to their ability to mimic calcium sensing. The pharmaceutical segment shows robust innovation with new drug formulations targeting hormone regulation, though surgical interventions remain a critical option for advanced cases. Vitamin D analogs play a complementary role in managing calcium homeostasis alongside primary treatments. |
| By Application |
|
Hospital Pharmacies dominate as the primary distribution channel due to the complex nature of treatment regimens requiring specialized administration. The growing prevalence of chronic kidney disease patients requiring ongoing management supports hospital pharmacy demand, while retail pharmacies are increasingly stocking maintenance medications for long-term therapy. |
| By End User |
|
Hospitals remain the predominant treatment setting due to the need for multidisciplinary care and close monitoring of patients with severe secondary hyperparathyroidism. Specialty clinics are gaining traction for ongoing management of chronic cases, while research institutes contribute to therapeutic advancements through clinical trials and novel treatment development. |
| By Treatment Approach |
|
Combination Therapy is increasingly preferred by clinicians to address multiple pathways involved in secondary hyperparathyroidism. The approach combines calcimimetics with vitamin D analogs and phosphate binders for comprehensive management. While parathyroidectomy remains reserved for refractory cases, its precision techniques continue to evolve with improved outcomes for qualifying patients. |
| By Disease Severity |
|
Moderate Cases represent the largest patient cohort benefiting from pharmacologic interventions and dietary management. Treatment protocols show significant variation along the severity spectrum, with aggressive management required for severe cases to prevent skeletal and vascular complications. The focus on early intervention in mild cases aims to prevent disease progression through timely biomarker monitoring. |
Innovative Therapies Drive Competitive Differentiation in SHPT Treatment Market
Amgen dominates the Secondary Hyperparathyroidism (SHPT) treatment market with its blockbuster drug Sensipar (cinacalcet), holding a significant revenue share. The market features a mix of large pharmaceutical companies and specialized biopharma firms developing novel calcimimetics, vitamin D analogs, and phosphate binders. Recent years have seen increased competition from biosimilars and next-generation therapies targeting mineral metabolism disorders.
Emerging players like OPKO Health and Deltanoid Pharmaceuticals are gaining traction with innovative treatment approaches, particularly for dialysis patients. Japanese pharma companies such as Kyowa Hakko Kirin and Astellas Pharma maintain strong regional presence with specialized formulations. The competitive landscape is further shaped by strategic collaborations between nephrology-focused biotechs and major pharma distributors.
List of Key Secondary Hyperparathyroidism Treatment Companies ProfiledAmgen Inc.
AbbVie Inc.
Astellas Pharma Inc.
KAI Pharmaceuticals (Amgen subsidiary)
Kyowa Hakko Kirin Co., Ltd.
Leo Pharma A/S
Sanofi S.A.
Deltanoid Pharmaceuticals
Teijin Pharma Limited
Chugai Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
The global Secondary Hyperparathyroidism Treatment market was valued at $3168 million in 2024 and is projected to reach $4576 million by 2031, growing at a CAGR of 5.5%. This growth is primarily driven by the increasing prevalence of chronic kidney disease (CKD), which is the most common cause of secondary hyperparathyroidism. Pharmaceutical innovations and improved diagnostic techniques are further accelerating market expansion.
Other TrendsDrug Class Segmentation Gains Importance
The treatment market is segmented into surgery, drugs, vitamin D, calcimimetics, and phosphate binders. Calcimimetics currently dominate the drug segment due to their efficacy in managing parathyroid hormone levels, holding over 40% market share in 2024. Pharmaceutical companies are investing heavily in developing next-generation calcimimetics with improved safety profiles.
Regional Market Dynamics and Distribution ChannelsNorth America leads the market with 45% share in 2024, followed by Europe and Asia-Pacific. Hospital pharmacies account for 60% of treatment distribution, with retail pharmacies gaining ground due to increasing outpatient treatment adoption. Emerging markets in Asia are projected to show the highest growth rates (7.2% CAGR) through 2031, fueled by improving healthcare infrastructure and rising CKD awareness.
Competitive Landscape and Pipeline DevelopmentsKey players like Amgen, AbbVie, and OPKO Health maintain strong market positions, collectively holding over 55% market share. The industry is witnessing increased M&A activity, with 12 major deals completed in 2023-2024 focused on expanding treatment portfolios. Five novel drug candidates targeting mineral metabolism pathways are currently in Phase III clinical trials, promising more treatment options by 2026.
Regional Analysis: Secondary Hyperparathyroidism Treatment MarketEurope
Europe represents the second-largest market for SHPT treatments, characterized by centralized healthcare systems and standardized treatment protocols. The region shows increasing adoption of combination therapies, particularly in Germany and France. Cost containment measures impact premium-priced innovative therapies, though exceptions exist for severe SHPT cases. Eastern European countries demonstrate growing demand as dialysis infrastructure improves, presenting new market opportunities for generic vitamin D analogs.
Asia-Pacific
The Asia-Pacific market exhibits the fastest growth rate due to expanding dialysis populations in India and China. Emerging economies focus on improving diagnosis rates through physician education programs. Japan leads in innovative treatment adoption, while Southeast Asian countries prioritize cost-effective generic alternatives. Market growth faces challenges from fragmented healthcare systems and limited reimbursement for newer therapies.
South America
Brazil dominates the South American SHPT treatment market, with public healthcare programs covering essential therapies. The region experiences constrained growth due to economic volatility and reliance on imported medications. Local manufacturing of generic vitamin D preparations helps address treatment accessibility for the growing CKD population.
Middle East & Africa
The Gulf Cooperation Council countries drive SHPT treatment adoption through well-funded healthcare systems, while Sub-Saharan Africa faces significant treatment gaps. Market growth concentrates in urban centers with specialized nephrology services, with international aid programs supporting basic treatment availability in low-income countries.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global secondary hyperparathyroidism treatment market was valued at USD 3.17 billion in 2024 and is projected to reach USD 4.58 billion by 2031.
Which key companies operate in Global Secondary Hyperparathyroidism Treatment Market?
-> Key players include Amgen, OPKO Health, AbbVie, Astellas Pharma, and Roche, among others.
-> Key growth drivers include increasing prevalence of chronic kidney disease, rising geriatric population, and improved diagnostic technologies.
-> North America holds the largest market share, while Asia-Pacific is the fastest-growing region.
-> Emerging trends include development of novel calcimimetics, precision medicine approaches, and strategic collaborations among pharmaceutical companies.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates